
    
      Randomized, double blind, parallel-group study in chronic, non-evolutive brain damaged
      patients (>6 months since stroke or brain trauma) and ambulating at <1.3 m/sec at maximal
      speed barefoot (AT10) Group 1: 150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF +
      100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB
      (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator
      clinical judgment.

      Group 2: 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin®
      distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum
      brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.

      Group 3: 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml)
      Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor
      digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical
      judgment.
    
  